What's Happening?
Aptar Pharma, a leader in drug delivery technologies, has announced progress on a research contract funded by the U.S. Food and Drug Administration (FDA). The contract, initiated in September 2023, focuses
on transitioning metered-dose inhalers (MDIs) to next-generation propellants (NGPs). The research aims to identify potential target product profiles for NGP MDIs to ensure they meet the critical quality attributes of existing MDIs. The project involves developing sensitive in vitro methods to support bioequivalence assessments. Since 2023, Aptar Pharma has conducted various scientific activities, including drug formulation experiments and computational modeling to understand aerosol physics with different propellant systems. The company has shared its findings with the FDA and plans to continue its research efforts.
Why It's Important?
The transition to next-generation propellants in inhalers is significant for both environmental and health reasons. Current propellants in MDIs contribute to greenhouse gas emissions, and developing alternatives could reduce the environmental impact. Additionally, ensuring that new propellants maintain the efficacy and safety of existing inhalers is crucial for patient health. Aptar Pharma's research, supported by the FDA, could lead to more sustainable inhaler options without compromising on performance. This development is particularly relevant for the pharmaceutical industry, which is under pressure to innovate while adhering to environmental regulations.
What's Next?
Aptar Pharma plans to continue its research under the FDA contract, with potential future studies including exploratory pharmacokinetic evaluations. The company aims to present its scientific findings at major conferences, such as the upcoming Respiratory Drug Delivery conference in May 2026. These efforts will contribute to the broader dissemination of knowledge and potentially influence regulatory standards for inhaler propellants. The ongoing collaboration with the FDA highlights the importance of regulatory support in advancing pharmaceutical innovations.
